Modelling Predictors of Molecular Response to Frontline Imatinib for Patients With Chronic Myeloid Leukaemia

PLoS ONE - United States
doi 10.1371/journal.pone.0168947
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Long-Term Impact of Molecular Response Fluctuations in Chronic Myeloid Leukaemia Patients Treated With Imatinib

British Journal of Haematology
Hematology
2017English

Gynaecomastia in Men With Chronic Myeloid Leukaemia After Imatinib

The Lancet
Medicine
2003English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Molecular Predictors of Response in Patients With Myeloid Neoplasms Treated With Lenalidomide

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Long-Term Molecular and Cytogenetic Response and Survival Outcomes With Imatinib 400 Mg, Imatinib 800 Mg, Dasatinib, and Nilotinib in Patients With Chronic-Phase Chronic Myeloid Leukaemia: Retrospective Analysis of Patient Data From Five Clinical Trials

The Lancet Haematology
Hematology
2015English

Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia

Epigenomics
Cancer ResearchGenetics
2015English

Functional Activity of Cd34-Positive Cells in Chronic Myeloid Leukemia Patients With Different Response to Imatinib Therapy

Experimental Oncology
Cancer ResearchOncology
2015English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib

Clinical Therapeutics
Pharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy